产品说明书

Nafamostat Mesylate

Print
Chemical Structure| 82956-11-4 同义名 : FUT-175;Nafamostat (mesylate);Nafamastat;Coahibitor;Nafamostat mesilate
CAS号 : 82956-11-4
货号 : A570309
分子式 : C21H25N5O8S2
纯度 : 98%
分子量 : 539.582
MDL号 : MFCD00941430
存储条件:

粉末 Sealed in dry,Room Temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 50 mg/mL(92.66 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

H2O: 30 mg/mL(55.6 mM),配合低频超声助溶

动物实验配方:
生物活性
描述 Nafamostat mesylate (FUT-175), a synthetic serine protease inhibitor, functions as an anticoagulant and exhibits both anticancer and antiviral effects. It is known to induce apoptosis by up-regulating the expression of tumor necrosis factor receptor-1 (TNFR1), and it is also used in studies related to the pathological thickening of arterial walls[1].[2].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01486485 Acute Kidney Injury Phase 3 Unknown August 2013 Korea, Republic of ... 展开 >> National Health Insurance Corporation Ilsan Hospital Recruiting Koyang, Korea, Republic of Contact: Tae Ik Chang, MD    82-31-900-0246    tichang@hanmail.net    Seoul National University Bundang Hospital Recruiting Seongnam, Korea, Republic of Contact: Sejoong Kim, MD, PhD    82-11-9196-5245    imsejoong@hanmail.net    Seoul National University Boramae Medical Center Recruiting Seoul, Korea, Republic of Contact: Jung Pyo Lee, MD, PhD    82-2-870-2261    kjwa1@medimail.co.kr    Seoul National University Hospital Recruiting Seoul, Korea, Republic of Contact: Su Mi Lee    82-2-2072-1705    promise131@hanmail.net 收起 <<
NCT01001403 Liver Transplantation ... 展开 >> Postreperfusion Syndrome 收起 << Phase 4 Completed - Korea, Republic of ... 展开 >> Seoul National University Hospital Seoul, Korea, Republic of, 110-744 收起 <<
NCT01761994 Acute Kidney Injury Phase 4 Completed - Korea, Republic of ... 展开 >> Severance Hospital Seoul, Korea, Republic of, 120-752 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.85mL

0.37mL

0.19mL

9.27mL

1.85mL

0.93mL

18.53mL

3.71mL

1.85mL

参考文献

[1]Uwagawa T, et al. Mechanisms of synthetic serine protease inhibitor (FUT‐175)‐mediated cell death [J]. Cancer: Interdisciplinary International Journal of the American Cancer Society, 2007, 109(10): 2142-2153.

[2]Tajima H, et al. Enhanced invasiveness of pancreatic adenocarcinoma cells stably transfected with cationic trypsinogen cDNA [J]. International journal of cancer, 2001, 94(5): 699-704.

[3]Yan Y, et al. Nafamostat mesylate as a broad-spectrum candidate for the treatment of flavivirus infections by targeting envelope proteins [J]. Antiviral research, 2022, 202: 105325.

[4]Sawada M, et al. Prevention of neointimal formation by a serine protease inhibitor, FUT-175, after carotid balloon injury in rats [J]. Stroke, 1999, 30(3): 644-650.